Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Nivolumab monotherapy shows effectiveness in advanced gastric cancer patients. Greater depth of response (DpR) correlates with improved progression-free survival (PFS) and overall survival (OS) in later-line treatment settings.
Area Of Science
- Oncology
- Gastroenterology
- Immunotherapy
Background
- Advanced gastric cancer (GC) presents significant treatment challenges.
- Nivolumab monotherapy is an option for previously treated advanced GC patients.
- Real-world data are crucial for understanding treatment effectiveness in routine clinical practice.
Purpose Of The Study
- To evaluate the real-world effectiveness of nivolumab monotherapy in advanced GC.
- To confirm survival outcomes and tumor behavior with nivolumab in a 2-year final analysis.
- To explore the association between depth of response (DpR) and survival in later-line therapy.
Main Methods
- Prospective observational study with a 2-year final analysis.
- Overall survival (OS) and progression-free survival (PFS) were primary endpoints.
- Tumor response evaluated using RECIST criteria; depth of response (DpR) analyzed for correlation with survival in patients receiving third- or later-line nivolumab.
Main Results
- Median OS was 5.8 months and median PFS was 1.8 months in 487 patients.
- Response rate (RR) was 14.5% in 282 patients with measurable lesions.
- Depth of response (DpR) significantly correlated with PFS (r=0.55) and OS (r=0.44); patients with DpR ≥30% demonstrated favorable survival.
Conclusions
- Nivolumab monotherapy is effective in advanced gastric cancer patients in real-world settings.
- Increased depth of response (DpR) is associated with longer PFS and OS.
- DpR serves as a potential predictive biomarker for nivolumab efficacy in later-line gastric cancer treatment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...